Cargando…

A reappraisal of generic bisphosphonates in osteoporosis

SUMMARY: The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed. INTRODUCTION: The purpose of this study is to review the impact of generic bisphosph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanis, J. A., Reginster, J.-Y., Kaufman, J.-M., Ringe, J.-D., Adachi, J. D., Hiligsmann, M., Rizzoli, R., Cooper, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249199/ https://www.ncbi.nlm.nih.gov/pubmed/21953472 http://dx.doi.org/10.1007/s00198-011-1796-6

Ejemplares similares

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
por: Rizzoli, R., et al.
Publicado: (2010)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2018)

Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2020)

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2022)

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2023)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2012)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation
por: Hiligsmann, M., et al.
Publicado: (2018)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
por: Hiligsmann, M., et al.
Publicado: (2019)

Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis
por: Hiligsmann, M., et al.
Publicado: (2013)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
por: Fuggle, N. R., et al.
Publicado: (2020)

Health Technology Assessment in Osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2013)

Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
por: Rizzoli, René, et al.
Publicado: (2011)

Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)

Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women
por: Chandran, M., et al.
Publicado: (2020)

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021)

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
por: Bergmann, P, et al.
Publicado: (2009)

Intervention thresholds and diagnostic thresholds in the management of osteoporosis
por: Kanis, John A., et al.
Publicado: (2022)

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
por: Rozenberg, S., et al.
Publicado: (2020)

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review
por: Cornelissen, D., et al.
Publicado: (2020)

Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
por: Olszynski, Wojciech P., et al.
Publicado: (2014)

Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)
por: Bruyère, O., et al.
Publicado: (2011)

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates
por: Abelson, A., et al.
Publicado: (2009)

Bisphosphonates adherence for treatment of osteoporosis
por: Vieira, Helena Parente, et al.
Publicado: (2013)

Physicians’ perspectives on the treatment of osteoporosis patients with bisphosphonates
por: Gu, Tao, et al.
Publicado: (2016)

Long-term use of bisphosphonates in osteoporosis
por: Alwahhabi, Basmah K., et al.
Publicado: (2017)

Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO)
por: Cianferotti, Luisella, et al.
Publicado: (2017)

Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment
por: Beaudart, C., et al.
Publicado: (2022)

The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2020)

A critical review of brand and generic alendronate for the treatment of osteoporosis
por: Brown, Jacques P, et al.
Publicado: (2013)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates
por: Heckman, George A, et al.
Publicado: (2002)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
por: Newcomb, P A, et al.
Publicado: (2010)

Long-term use of bisphosphonates in osteoporosis
por: Sadat-Ali, Mir, et al.
Publicado: (2017)

SCOPE: a scorecard for osteoporosis in Europe
por: Kanis, J. A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_44qma2javmjfv7rh3mgvg8df79